The burden of healthcare costs associated with prostate cancer in Ireland
<h4>Purpose</h4> <p>With one of the highest incidence rates across Europe and the rest of the World in 2012, the Republic of Ireland (RoI) has experienced significant increases in prostate cancer (PCa) incidence since 1994. The main driver is the widespread use of PSA testing whic...
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Journal article |
| Pubblicazione: |
Wichtig Publishing
2016
|
| _version_ | 1826265504641187840 |
|---|---|
| author | Burns, R Leal, J Wolstenholme, J O’Neill, C Sullivan, F Drummond, F Sharp, L |
| author_facet | Burns, R Leal, J Wolstenholme, J O’Neill, C Sullivan, F Drummond, F Sharp, L |
| author_sort | Burns, R |
| collection | OXFORD |
| description | <h4>Purpose</h4> <p>With one of the highest incidence rates across Europe and the rest of the World in 2012, the Republic of Ireland (RoI) has experienced significant increases in prostate cancer (PCa) incidence since 1994. The main driver is the widespread use of PSA testing which is used to detect PCa. This is expected to have significant implications on resource use in the RoI. The focus of this paper was to (i) derive costs for the PCa pathway, from diagnosis to treatment, and (ii) estimate overall healthcare expenditure for PCa in the RoI.</p> <h4>Methods</h4> <p>With one of the highest incidence rates across Europe and the rest of the World in 2012, the Republic of Ireland (RoI) has experienced significant increases in prostate cancer (PCa) incidence since 1994. The main driver is the widespread use of PSA testing which is used to detect PCa. This is expected to have significant implications on resource use in the RoI. The focus of this paper was to (i) derive costs for the PCa pathway, from diagnosis to treatment, and (ii) estimate overall healthcare expenditure for PCa in the RoI.</p> <h4>Results</h4> <p>The overall estimated burden of healthcare costs associated for those diagnosed with PCa and receiving care (up to four year post-diagnosis) or dying from PCa in 2010 was approximately €45.6 million. The overall cost associated with detection, via PSA testing, for those diagnosed with PCa in 2010 (n=3,287) was €366,369. Treatment costs varied considerably with the most costly treatment being chemotherapy and radical prostatectomy (unit cost €11,278 and €7,324, respectively).</p> <h4>Conclusion</h4> <p>PCa incidence partly due to high levels of PSA testing has significant resource utilisation implications in the RoI.</p> |
| first_indexed | 2024-03-06T20:24:44Z |
| format | Journal article |
| id | oxford-uuid:2f0548ec-ae22-4dbc-8cc0-7632c305be2d |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:24:44Z |
| publishDate | 2016 |
| publisher | Wichtig Publishing |
| record_format | dspace |
| spelling | oxford-uuid:2f0548ec-ae22-4dbc-8cc0-7632c305be2d2022-03-26T12:52:38ZThe burden of healthcare costs associated with prostate cancer in IrelandJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2f0548ec-ae22-4dbc-8cc0-7632c305be2dSymplectic Elements at OxfordWichtig Publishing2016Burns, RLeal, JWolstenholme, JO’Neill, CSullivan, FDrummond, FSharp, L <h4>Purpose</h4> <p>With one of the highest incidence rates across Europe and the rest of the World in 2012, the Republic of Ireland (RoI) has experienced significant increases in prostate cancer (PCa) incidence since 1994. The main driver is the widespread use of PSA testing which is used to detect PCa. This is expected to have significant implications on resource use in the RoI. The focus of this paper was to (i) derive costs for the PCa pathway, from diagnosis to treatment, and (ii) estimate overall healthcare expenditure for PCa in the RoI.</p> <h4>Methods</h4> <p>With one of the highest incidence rates across Europe and the rest of the World in 2012, the Republic of Ireland (RoI) has experienced significant increases in prostate cancer (PCa) incidence since 1994. The main driver is the widespread use of PSA testing which is used to detect PCa. This is expected to have significant implications on resource use in the RoI. The focus of this paper was to (i) derive costs for the PCa pathway, from diagnosis to treatment, and (ii) estimate overall healthcare expenditure for PCa in the RoI.</p> <h4>Results</h4> <p>The overall estimated burden of healthcare costs associated for those diagnosed with PCa and receiving care (up to four year post-diagnosis) or dying from PCa in 2010 was approximately €45.6 million. The overall cost associated with detection, via PSA testing, for those diagnosed with PCa in 2010 (n=3,287) was €366,369. Treatment costs varied considerably with the most costly treatment being chemotherapy and radical prostatectomy (unit cost €11,278 and €7,324, respectively).</p> <h4>Conclusion</h4> <p>PCa incidence partly due to high levels of PSA testing has significant resource utilisation implications in the RoI.</p> |
| spellingShingle | Burns, R Leal, J Wolstenholme, J O’Neill, C Sullivan, F Drummond, F Sharp, L The burden of healthcare costs associated with prostate cancer in Ireland |
| title | The burden of healthcare costs associated with prostate cancer in Ireland |
| title_full | The burden of healthcare costs associated with prostate cancer in Ireland |
| title_fullStr | The burden of healthcare costs associated with prostate cancer in Ireland |
| title_full_unstemmed | The burden of healthcare costs associated with prostate cancer in Ireland |
| title_short | The burden of healthcare costs associated with prostate cancer in Ireland |
| title_sort | burden of healthcare costs associated with prostate cancer in ireland |
| work_keys_str_mv | AT burnsr theburdenofhealthcarecostsassociatedwithprostatecancerinireland AT lealj theburdenofhealthcarecostsassociatedwithprostatecancerinireland AT wolstenholmej theburdenofhealthcarecostsassociatedwithprostatecancerinireland AT oneillc theburdenofhealthcarecostsassociatedwithprostatecancerinireland AT sullivanf theburdenofhealthcarecostsassociatedwithprostatecancerinireland AT drummondf theburdenofhealthcarecostsassociatedwithprostatecancerinireland AT sharpl theburdenofhealthcarecostsassociatedwithprostatecancerinireland AT burnsr burdenofhealthcarecostsassociatedwithprostatecancerinireland AT lealj burdenofhealthcarecostsassociatedwithprostatecancerinireland AT wolstenholmej burdenofhealthcarecostsassociatedwithprostatecancerinireland AT oneillc burdenofhealthcarecostsassociatedwithprostatecancerinireland AT sullivanf burdenofhealthcarecostsassociatedwithprostatecancerinireland AT drummondf burdenofhealthcarecostsassociatedwithprostatecancerinireland AT sharpl burdenofhealthcarecostsassociatedwithprostatecancerinireland |